Table 1.
Trial characteristics tabulated by recruitment period and type of funding
| Bladder cancer | Head and neck cancer | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Recruitment period | 2013–2017 | 2018–2023 | Total | 2013–2017 | 2018–2023 | Total | ||||
| Type of funding | Non-industry | Industry | Non-industry | Industry | Non-industry | Industry | Non-industry | Industry | ||
| 9 | 8 | 1 | 20 | 38 | 9 | 7 | 1 | 13 | 30 | |
| Phase | ||||||||||
| II | 4 | 4 | 0 | 4 | 12 | 1 | 3 | 0 | 7 | 11 |
| II/III | 1 | 0 | 0 | 1 | 2 | 0 | 0 | 0 | 2 | 2 |
| III | 4 | 4 | 1 | 15 | 24 | 8 | 4 | 1 | 4 | 17 |
| Trial sponsor | ||||||||||
| Non-commercial | 9 | 4 | 1 | 4 | 18 | 8 | 0 | 1 | 1 | 10 |
| Commercial | 0 | 4 | 0 | 16 | 20 | 1 | 7 | 0 | 12 | 20 |
| Trial type | ||||||||||
| CTIMP | 3 | 7 | 0 | 20 | 30 | 6 | 7 | 0 | 13 | 26 |
| Non CTIMP | 6 | 1 | 1 | 0 | 8 | 3 | 0 | 1 | 0 | 4 |
| Intervention type | ||||||||||
| Pharmacological | 2 | 7 | 0 | 15 | 24 | 2 | 6 | 0 | 11 | 19 |
| Radiotherapy | 2 | 0 | 0 | 0 | 2 | 3 | 0 | 1 | 0 | 4 |
| Surgical | 3 | 0 | 1 | 0 | 4 | |||||
| Other | 2 | 0 | 0 | 0 | 2 | |||||
| Mixed regimens | 1 | 0 | 0 | 5 | 6 | 4 | 1 | 0 | 2 | 7 |
| Disease stage: bladder cancer | ||||||||||
| Any bladder cancer | 1 | 0 | 1 | 0 | 2 | |||||
| NMIBC | 5 | 1 | 0 | 4 | 10 | |||||
| MIBC (any) | 1 | 0 | 0 | 1 | 2 | |||||
| MIBC (non-metastatic) | 2 | 1 | 0 | 10 | 13 | |||||
| MIBC (metastatic) | 0 | 6 | 0 | 5 | 11 | |||||
| Disease stage: head and neck cancer | ||||||||||
| Non-metastatic or locally advanced | 5 | 1 | 0 | 2 | 8 | |||||
| Metastatic or recurrent | 0 | 6 | 0 | 11 | 17 | |||||
| Multiple disease stages | 4 | 0 | 1 | 0 | 5 | |||||